Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Klebsiella pneumoniae

References

• Fupin H, Yan G, Demei Z, et al. CHINET surveillance of antimicrobial resistance among the bacterial isolates in 2021. Chin J Infection Chemother. 2022;22(5):521–530. doi:10.16718/j.1009-7708.2022.05.001
   Google Scholar
• Paniagua-García M, Bravo-Ferrer JM, Pérez-Galera S, et al. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA). Clin Microbiol Infect. 2024;30(2):223–230. doi:10.1016/j.cmi.2023.11.008
   PubMed Web of Science ®Google Scholar
• Yang W, Ding L, Han R, et al. Current status and trends of antimicrobial resistance among clinical isolates in China: a retrospective study of CHINET from 2018 to 2022. One Health Adv. 2023;1(1):8. doi:10.1186/s44280-023-00009-9
   Google Scholar
• Han R, Shi Q, Wu S, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among Carbapenem-Resistant Enterobacteriaceae Isolated from adult and children patients in China. Front Cell Infect Microbiol. 2020;10:314. doi:10.3389/fcimb.2020.00314
   PubMed Web of Science ®Google Scholar
• van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: second-generation beta-Lactam/beta-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016;63(2):234–241. doi:10.1093/cid/ciw243
   PubMed Web of Science ®Google Scholar
• Sharma R, Park TE, Moy S. Ceftazidime-Avibactam: a novel Cephalosporin/beta-Lactamase inhibitor combination for the treatment of resistant gram-negative organisms. Clin Ther. 2016;38(3):431–444. doi:10.1016/j.clinthera.2016.01.018
   PubMed Web of Science ®Google Scholar
• Yin D, Wu S, Yang Y, et al. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63(4). doi:10.1128/aac.02431-18
   Web of Science ®Google Scholar
• Guo Y, Han R, Jiang B, et al. In Vitro Activity of New β-Lactam-β-Lactamase inhibitor combinations and comparators against clinical isolates of gram-negative Bacilli: results from the China Antimicrobial Surveillance Network (CHINET) in 2019. Microbiol Spectr. 2022;10(4):e0185422. doi:10.1128/spectrum.01854-22
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang J, Wang R, et al. Resistance to ceftazidime-avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18–27. doi:10.1016/j.jgar.2019.12.009
   PubMed Web of Science ®Google Scholar
• Hobson CA, Bonacorsi S, Jacquier H, et al. KPC Beta-Lactamases are permissive to insertions and deletions conferring substrate spectrum modifications and resistance to Ceftazidime-Avibactam. Antimicrob Agents Chemother. 2020;64(12). doi:10.1128/aac.01175-20
   PubMed Web of Science ®Google Scholar
• Ding L, Shen S, Chen J, et al. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health. Clin Microbiol Rev. 2023;36(4):e0000823. doi:10.1128/cmr.00008-23
   PubMed Web of Science ®Google Scholar
• Tian D, Liu X, Chen W, et al. Prevalence of hypervirulent and carbapenem-resistant Klebsiella pneumoniae under divergent evolutionary patterns. Emerg Microbes Infect. 2022;11(1):1936–1949. doi:10.1080/22221751.2022.2103454
   PubMed Web of Science ®Google Scholar
• Tian D, Wang M, Zhou Y, et al. Genetic diversity and evolution of the virulence plasmids encoding aerobactin and salmochelin in Klebsiella pneumoniae. Virulence. 2021;12(1):1323–1333. doi:10.1080/21505594.2021.1924019
   PubMed Web of Science ®Google Scholar
• Ping L, Mavridou DA, Emberly E, et al. Vital dye reaction and granule localization in periplasm of Escherichia coli. PLoS One. 2012;7(6):e38427. doi:10.1371/journal.pone.0038427
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 33th ed. Wayne (PA): CLSI supplement M100. Clinical and Laboratory Standards Institute; 2023.
   Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, 2024. https://www.eucast.org/clinical_breakpoints.
   Google Scholar
• U.S. Food and Drug Administration. Tigecycline-Injection products; 2023. available at https://www.fda.gov/drugs/development-resources/tigecycline-injection-products.
   Google Scholar
• Poirel L, Walsh TR, Cuvillier V, et al. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119–123. doi:10.1016/j.diagmicrobio.2010.12.002
   PubMed Web of Science ®Google Scholar
• Shi Q, Han R, Guo Y, et al. Multiple Novel Ceftazidime-Avibactam-Resistant Variants of blaKPC-2-Positive Klebsiella pneumoniae in two patients. Microbiol Spectr. 2022;10(3):e0171421. doi:10.1128/spectrum.01714-21
   PubMed Web of Science ®Google Scholar
• Li X, Quan J, Ke H, et al. Emergence of a KPC variant conferring resistance to Ceftazidime-Avibactam in a Widespread ST11 Carbapenem-Resistant Klebsiella pneumoniae Clone in China. Front Microbiol. 2021;12:724272. doi:10.3389/fmicb.2021.724272
   PubMed Web of Science ®Google Scholar
• Li X, Ke H, Wu W, et al. Molecular mechanisms driving the In Vivo Development of KPC-71-mediated resistance to Ceftazidime-Avibactam during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. mSphere. 2021;6(6):e0085921. doi:10.1128/mSphere.00859-21
   PubMed Web of Science ®Google Scholar
• DelaFuente J, Rodriguez-Beltran J, San Millan A. Methods to study fitness and compensatory adaptation in plasmid-carrying bacteria. Methods Mol Biol. 2020;2075:371–382. doi:10.1007/978-1-4939-9877-7_26
   PubMedGoogle Scholar
• Shi Q, Yin D, Han R, et al. Emergence and recovery of Ceftazidime-avibactam resistance in blaKPC-33-Harboring Klebsiella pneumoniae sequence Type 11 isolates in China. Clin Infect Dis. 2020;71(Supplement_4):S436–s439. doi:10.1093/cid/ciaa1521
   PubMedGoogle Scholar
• Huang X, Shen S, Chang F, et al. Emergence of KPC-134, a KPC-2 variant associated with ceftazidime-avibactam resistance in a ST11 Klebsiella pneumoniae clinical strain. Microbiol Spectr. 2023;11(5):e0072523. doi:10.1128/spectrum.00725-23
   PubMed Web of Science ®Google Scholar
• Dietl B, Martínez LM, Calbo E, et al. Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales. Future Microbiol. 2020;15:473–484. doi:10.2217/fmb-2020-0012
   PubMed Web of Science ®Google Scholar
• Li D, Li K, Dong H, et al. Ceftazidime-Avibactam resistance in Klebsiella pneumoniae Sequence Type 11 Due to a Mutation in Plasmid-Borne blaKPC-2 to blaKPC-33, in Henan, China. Infect Drug Resist. 2021;14:1725–1731. doi:10.2147/idr.S306095
   PubMed Web of Science ®Google Scholar
• Alsenani TA, Viviani SL, Kumar V, et al. Structural characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-loop destabilization as a mechanism of resistance to Ceftazidime-Avibactam. Antimicrob Agents Chemother. 2022;66(4):e0241421. doi:10.1128/aac.02414-21
   PubMed Web of Science ®Google Scholar
• Galdadas I, Qu S, Oliveira ASF, et al. Allosteric communication in class A β-lactamases occurs via cooperative coupling of loop dynamics. Elife. 2021: 10. doi:10.7554/eLife.66567
   Web of Science ®Google Scholar
• Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the Omega-loop. J Antimicrob Chemother. 2015;70(8):2279–2286. doi:10.1093/jac/dkv094
   PubMed Web of Science ®Google Scholar
• Barnes MD, Winkler ML, Taracila MA, et al. Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and resistance to Ceftazidime-Avibactam: unique antibiotic-resistant phenotypes emerge from β-Lactamase protein engineering. mBio. 2017;8(5):e00528–17. doi:10.1128/mBio.00528-17
   PubMed Web of Science ®Google Scholar
• Chen L, Mathema B, Chavda KD, et al. Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding. Trends Microbiol. 2014;22(12):686–696. doi:10.1016/j.tim.2014.09.003
   PubMed Web of Science ®Google Scholar
• Varani A, He S, Siguier P, et al. The IS6 family, a clinically important group of insertion sequences including IS26. Mob DNA. 2021;12(1):11. doi:10.1186/s13100-021-00239-x
   PubMed Web of Science ®Google Scholar
• Zhang X, Li F, Cui S, et al. Prevalence and distribution characteristics of blaKPC-2 and blaNDM-1 Genes in Klebsiella pneumoniae. Infect Drug Resist. 2020;13:2901–2910. doi:10.2147/idr.S253631
   PubMed Web of Science ®Google Scholar
• Shi L, Feng J, Zhan Z, et al. Comparative analysis of blaKPC-2- and rmtB-carrying IncFII-family pKPC-LK30/pHN7A8 hybrid plasmids from Klebsiella pneumoniae CG258 strains disseminated among multiple Chinese hospitals. Infect Drug Resist. 2018;11:1783–1793. doi:10.2147/idr.S171953
   PubMed Web of Science ®Google Scholar
• Huang J, Hu X, Zhao Y, et al. Genetic factors associated with enhanced blaKPC Expression in Tn3/Tn4401 Chimeras. Antimicrob Agents Chemother. 2020;64(3). doi:10.1128/aac.01836-19
   Web of Science ®Google Scholar
• Dong N, Yang X, Zhang R, et al. Tracking microevolution events among ST11 carbapenemase-producing hypervirulent Klebsiella pneumoniae outbreak strains. Emerg Microbes Infect. 2018;7(1):146. doi:10.1038/s41426-018-0146-6
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang T, Chen L, et al. Virulence factors in Hypervirulent Klebsiella pneumoniae. Front Microbiol. 2021;12:642484. doi:10.3389/fmicb.2021.642484
   PubMed Web of Science ®Google Scholar
• Hornick DB, Allen BL, Horn MA, et al. Adherence to respiratory epithelia by recombinant Escherichia coli expressing Klebsiella pneumoniae type 3 fimbrial gene products. Infect Immun. 1992;60(4):1577–1588. doi:10.1128/iai.60.4.1577-1588.1992
   PubMed Web of Science ®Google Scholar
• D'Apolito D, Arena F, Conte V, et al. Phenotypical and molecular assessment of the virulence potential of KPC-3-producing Klebsiella pneumoniae ST392 clinical isolates. Microbiol Res. 2020;240:126551. doi:10.1016/j.micres.2020.126551
   PubMedGoogle Scholar
• Mohamed NA, Alrawy MH, Makbol RM, et al. Type VI secretion system (T6SS) in Klebsiella pneumoniae, relation to antibiotic resistance and biofilm formation. Iran J Microbiol. 2023;15(5):601–608. doi:10.18502/ijm.v15i5.13865
   PubMed Web of Science ®Google Scholar
• Yang Q, Jia X, Zhou M, et al. Emergence of ST11-K47 and ST11-K64 hypervirulent carbapenem-resistant Klebsiella pneumoniae in bacterial liver abscesses from China: a molecular, biological, and epidemiological study. Emerg Microbes Infect. 2020;9(1):320–331. doi:10.1080/22221751.2020.1721334
   PubMed Web of Science ®Google Scholar
• Douradinha B. Should multidrug resistant Klebsiella pneumoniae strains displaying hypervirulent traits be reclassified as either ultravirulent or supervirulent? Microbiol Res. 2023;275:127446. doi:10.1016/j.micres.2023.127446
   PubMedGoogle Scholar